Status:
COMPLETED
Post Marketing Surveillance Study of Sifrol® in Patients With Idiopathic Parkinson's Disease
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Parkinson Disease
Eligibility:
All Genders
Brief Summary
Study to document pramipexole dosing during monotherapy, occurrence of fluctuations and dyskinesias, dose increases after deterioration of Parkinson's disease (PD) symptoms, assessment of the reasons ...
Eligibility Criteria
Inclusion
- Diagnosis of early stage idiopathic Parkinson's Disease
- No pre-treatment with any dopaminergic treatment (de novo patients), or Pre-treatment with L-Dopa at doses of \< 200 mg/d
Exclusion
- Treating physicians are asked to consider the regulation described in the Summary of Product Characteristics (SmPC) for the treatment with pramipexole
Key Trial Info
Start Date :
February 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
442 Patients enrolled
Trial Details
Trial ID
NCT02248181
Start Date
February 1 2004
Last Update
September 25 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.